Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Tenon Medical (NASDAQ:TNON) announced FDA 510(k) clearance for the SImmetry+ SI Joint Fusion System on October 21, 2025. The minimally invasive lateral-access system uses new 3D-printed titanium implants, joint decortication, bone graft delivery, and fixation to enable SI joint fusion. Tenon plans an alpha launch targeting year-end 2025 with select physician users to gather initial feedback ahead of broader commercial rollout. SImmetry+ joins Tenon's Catamaran platform, expanding multi-approach SI fusion options supported by published prospective studies.
Tenon Medical (NASDAQ:TNON) announced compelling 12-month results from its MAINSAIL™ study evaluating the Catamaran® SI Joint Fusion System. The study showed significant clinical improvements, with pain scores (VAS) decreasing from 78.8mm to 23.0mm and disability scores (ODI) improving from 51.6% to 20.8%. 83% of patients demonstrated unequivocal fusion evidence at 12 months.
The study, involving 24 patients across six U.S. clinical sites, reported no serious adverse events and high patient satisfaction, with 83.3% reporting satisfaction at 12 months. The surgical efficiency was notable, with 45.7% of procedures completed in under 45 minutes. These results exceed average improvements reported in previous literature for SI joint fusion procedures.
Tenon Medical (NASDAQ:TNON) has announced the full commercial launch of its Catamaran® SE SI Joint Fusion System, expanding its implant portfolio for sacroiliac joint fusion procedures. The new system features a smaller implant profile compared to the original Catamaran Fixation Device, designed for patients with smaller SI joint anatomy or revision surgeries.
The system includes a dedicated instrument set with a manual drilling option and leverages enhanced commercial capabilities from the recent SiVantage acquisition. The titanium implant has demonstrated strong clinical performance with over 1,000 devices implanted to date, showing promising early results in the MAINSAIL Clinical Study for achieving successful fusion.
Tenon Medical (NASDAQ:TNON) reported Q2 2025 financial results, highlighting its strategic acquisition of SiVantage portfolio. The company posted revenue of $0.6 million, down from $0.9 million in Q2 2024, with a net loss of $2.8 million compared to $3.8 million in the prior year.
Key highlights include operating expenses reduction of 29% year-over-year, FDA clearance for Catamaran® as an adjunct to thoracolumbar fixation, and successful completion of initial case series. The company maintained a strong financial position with $7.8 million in cash and no outstanding debt as of June 30, 2025.
The SiVantage acquisition is expected to accelerate topline growth through immediate revenue generation, expanded market access, and strengthened hospital pathways, with integration planned over the next 60-90 days.
Tenon Medical (NASDAQ:TNON), a company focused on Sacroiliac Joint (SIJ) disorders treatment, will release its Q2 2025 financial results after market close on Wednesday, August 13, 2025.
The company will host a conference call at 4:30 p.m. Eastern Time on the same day, featuring a Q&A session with covering analysts. The call will be accessible via telephone and webcast, with replay available through August 27, 2025 on Tenon's Investor Relations website.
Tenon Medical (NASDAQ:TNON) has acquired sacroiliac joint-specific assets from SiVantage, including their SImmetry® and SImmetry+™ technologies. The strategic acquisition transforms Tenon into a multi-product, multi-approach sacro-pelvic organization, expanding its portfolio across multiple approaches to sacro-pelvic anatomy.
The transaction brings critical technologies, intellectual property, and key leadership to Tenon, with SiVantage's co-founders joining as Chief Innovations Officer and Chief Commercial Officer. The deal structure includes an upfront cash component and equity issuance, with most consideration tied to future performance milestones. Integration is expected to complete in Q4 2025.
The acquisition immediately strengthens Tenon's product pipeline and is expected to contribute to revenue, supported by extensive clinical data demonstrating safety and performance in sacroiliac joint fusion procedures.
Tenon Medical (NASDAQ: TNON), a healthcare company focused on Sacroiliac Joint (SIJ) disorders, has scheduled its Q1 2025 financial results announcement for May 13, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern Time, featuring a Q&A session with covering analysts.
Investors can access the call through:
- US Dial-in: 1-877-407-0792
- International Dial-in: 1-201-689-8263
Participants are advised to dial in 10 minutes before the call starts. A replay will be available through May 28, 2025, via the company's IR website or by phone (US: 1-844-512-2921, International: 1-412-317-6671) using access code 13752970.
Tenon Medical (NASDAQ:TNON), a company focused on sacroiliac joint disorders treatment, has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will issue 1,271,500 shares of common stock at $2.00 per share to a single healthcare focused institutional investor.
In a concurrent private placement, Tenon will also issue warrants to purchase up to 1,271,500 shares of common stock with an exercise price of $2.00 per share. These warrants will be immediately exercisable and expire after five years.
The offering is expected to close around March 27, 2025. A.G.P./Alliance Global Partners is serving as the sole placement agent. The proceeds will be used for working capital and general corporate purposes.
Tenon Medical (NASDAQ:TNON), a company focused on sacroiliac joint disorders treatment, has announced a registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules. The company will issue 733,500 shares of common stock at $2.00 per share to a single healthcare focused institutional investor.
In the concurrent private placement, Tenon will issue warrants to purchase up to 733,500 additional shares at an exercise price of $2.00 per share, exercisable immediately with a five-year expiration. The offering, expected to close around March 26, 2025, aims to raise approximately $1.5 million in gross proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent.